Johannes Zuber

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1825894/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Dysregulated RNA polyadenylation contributes to metabolic impairment in non-alcoholic fatty liver disease. Nucleic Acids Research, 2022, 50, 3379-3393.	6.5	14
2	<scp>BRD4</scp> degradation blocks expression of <scp>MYC</scp> and multiple forms of stem cell resistance in Ph ⁺ chronic myeloid leukemia. American Journal of Hematology, 2022, 97, 1215-1225.	2.0	14
3	Isolating live cell clones from barcoded populations using CRISPRa-inducible reporters. Nature Biotechnology, 2021, 39, 174-178.	9.4	63
4	XPO7 is a tumor suppressor regulating p21 ^{CIP1} -dependent senescence. Genes and Development, 2021, 35, 379-391.	2.7	9
5	Ubiquitylation of MYC couples transcription elongation with double-strand break repair at active promoters. Molecular Cell, 2021, 81, 830-844.e13.	4.5	28
6	Precision Medicine in Hematology 2021: Definitions, Tools, Perspectives, and Open Questions. HemaSphere, 2021, 5, e536.	1.2	11
7	Functional interrogation of a SARS-CoV-2 host protein interactome identifies unique and shared coronavirus host factors. Cell Host and Microbe, 2021, 29, 267-280.e5.	5.1	127
8	A functional LSD1 coregulator screen reveals a novel transcriptional regulatory cascade connecting R-loop homeostasis with epigenetic regulation. Nucleic Acids Research, 2021, 49, 4350-4370.	6.5	13
9	Core-binding factor leukemia hijacks the T-cell–prone PU.1 antisense promoter. Blood, 2021, 138, 1345-1358.	0.6	12
10	Selective Requirement of MYB for Oncogenic Hyperactivation of a Translocated Enhancer in Leukemia. Cancer Discovery, 2021, 11, 2868-2883.	7.7	25
11	A genome-wide CRISPR/Cas9 screen to identify phagocytosis modulators in monocytic THP-1 cells. Scientific Reports, 2021, 11, 12973.	1.6	9
12	Prevalence of RT-qPCR-detected SARS-CoV-2 infection at schools: First results from the Austrian School-SARS-CoV-2 prospective cohort study. Lancet Regional Health - Europe, The, 2021, 5, 100086.	3.0	33
13	Functional Analysis of Non-Genetic Resistance to Platinum in Epithelial Ovarian Cancer Reveals a Role for the MBD3-NuRD Complex in Resistance Development. Cancers, 2021, 13, 3801.	1.7	6
14	Acquired resistance to anti-MAPK targeted therapy confers an immune-evasive tumor microenvironment and cross-resistance to immunotherapy in melanoma. Nature Cancer, 2021, 2, 693-708.	5.7	102
15	Sensitivity and specificity of the antigen-based anterior nasal self-testing programme for detecting SARS-CoV-2 infection in schools, Austria, March 2021. Eurosurveillance, 2021, 26, .	3.9	7
16	Inhibition of CBP synergizes with the RNA-dependent mechanisms of Azacitidine by limiting protein synthesis. Nature Communications, 2021, 12, 6060.	5.8	12
17	Results of WICOVIR Gargle Pool PCR Testing in German Schools Based on the First 100,000 Tests. Frontiers in Pediatrics, 2021, 9, 721518.	0.9	14
18	AKIRIN2 controls the nuclear import of proteasomes in vertebrates. Nature, 2021, 599, 491-496.	13.7	55

#	Article	IF	CITATIONS
19	Agent-based simulations for protecting nursing homes with prevention and vaccination strategies. Journal of the Royal Society Interface, 2021, 18, 20210608.	1.5	11
20	SFPQ Depletion Is Synthetically Lethal with BRAFV600E in Colorectal Cancer Cells. Cell Reports, 2020, 32, 108184.	2.9	19
21	Cohesin-Dependent and -Independent Mechanisms Mediate Chromosomal Contacts between Promoters and Enhancers. Cell Reports, 2020, 32, 107929.	2.9	106
22	Rational discovery of molecular glue degraders via scalable chemical profiling. Nature Chemical Biology, 2020, 16, 1199-1207.	3.9	197
23	A human tissue screen identifies a regulator of ER secretion as a brain-size determinant. Science, 2020, 370, 935-941.	6.0	101
24	The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1. Blood, 2020, 136, 957-973.	0.6	35
25	Multilayered VBC score predicts sgRNAs that efficiently generate loss-of-function alleles. Nature Methods, 2020, 17, 708-716.	9.0	77
26	Leukemia Cell of Origin Influences Apoptotic Priming and Sensitivity to LSD1 Inhibition. Cancer Discovery, 2020, 10, 1500-1513.	7.7	24
27	Reduced replication origin licensing selectively kills KRAS-mutant colorectal cancer cells via mitotic catastrophe. Cell Death and Disease, 2020, 11, 499.	2.7	4
28	Parallel PRC2/cPRC1 and vPRC1 pathways silence lineage-specific genes and maintain self-renewal in mouse embryonic stem cells. Science Advances, 2020, 6, eaax5692.	4.7	46
29	CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood, 2020, 136, 387-400.	0.6	46
30	Inducible knock-out of BCL6 in lymphoma cells results in tumor stasis. Oncotarget, 2020, 11, 875-890.	0.8	22
31	STAG1 vulnerabilities for exploiting cohesin synthetic lethality in STAG2-deficient cancers. Life Science Alliance, 2020, 3, e202000725.	1.3	19
32	Abstract 6221: Targeting IAP in cancer: BI 891065 a potent small molecule SMAC mimetic that synergizes with immune checkpoint inhibition. , 2020, , .		0
33	Abstract 6119: RNAi rat models for drug discovery. , 2020, , .		Ο
34	Core Binding Factor Leukemias Utilize a Physiologic Sense/Antisense Promoter Switch Employed By T-Cells. Blood, 2020, 136, 40-41.	0.6	0
35	Interconversion between Tumorigenic and Differentiated States in Acute Myeloid Leukemia. Cell Stem Cell, 2019, 25, 258-272.e9.	5.2	60
36	Apelin inhibition prevents resistance and metastasis associated with antiâ€angiogenic therapy. EMBO Molecular Medicine, 2019, 11, e9266.	3.3	72

#	Article	IF	CITATIONS
37	A kinase-independent role for CDK8 in BCR-ABL1+ leukemia. Nature Communications, 2019, 10, 4741.	5.8	33
38	Integrative analysis of pooled CRISPR genetic screens using MAGeCKFlute. Nature Protocols, 2019, 14, 756-780.	5.5	260
39	Quantification of experimentally induced nucleotide conversions in high-throughput sequencing datasets. BMC Bioinformatics, 2019, 20, 258.	1.2	86
40	MTHFD1 interaction with BRD4 links folate metabolism to transcriptional regulation. Nature Genetics, 2019, 51, 990-998.	9.4	61
41	Sequencing cell-type-specific transcriptomes with SLAM-ITseq. Nature Protocols, 2019, 14, 2261-2278.	5.5	13
42	The histone chaperone CAF-1 cooperates with the DNA methyltransferases to maintain <i>Cd4</i> silencing in cytotoxic T cells. Genes and Development, 2019, 33, 669-683.	2.7	27
43	Functional-genetic approaches to understanding drug response and resistance. Current Opinion in Genetics and Development, 2019, 54, 41-47.	1.5	3
44	All-trans retinoic acid enhances, and a pan-RAR antagonist counteracts, the stem cell promoting activity of EVI1 in acute myeloid leukemia. Cell Death and Disease, 2019, 10, 944.	2.7	18
45	Human blood vessel organoids as aÂmodel ofÂdiabetic vasculopathy. Nature, 2019, 565, 505-510.	13.7	500
46	Leukemia Cell of Origin Influences p53 Activity and Therapeutic Sensitivity Via an Evi1-Dependent Mechanism. Blood, 2019, 134, 109-109.	0.6	0
47	The novel BET bromodomain inhibitor BI 894999 represses super-enhancer-associated transcription and synergizes with CDK9 inhibition in AML. Oncogene, 2018, 37, 2687-2701.	2.6	66
48	SLAM-seq defines direct gene-regulatory functions of the BRD4-MYC axis. Science, 2018, 360, 800-805.	6.0	284
49	The IAP family member BRUCE regulates autophagosome–lysosome fusion. Nature Communications, 2018, 9, 599.	5.8	80
50	Drug-induced inhibition of phosphorylation of STAT5 overrides drug resistance in neoplastic mast cells. Leukemia, 2018, 32, 1016-1022.	3.3	20
51	Senescence-associated reprogramming promotes cancer stemness. Nature, 2018, 553, 96-100.	13.7	714
52	Pooled Generation of Lentiviral Tetracycline-Regulated microRNA Embedded Short Hairpin RNA Libraries. Human Gene Therapy Methods, 2018, 29, 16-29.	2.1	3
53	Mutations in Vps15 perturb neuronal migration in mice and are associated with neurodevelopmental disease in humans. Nature Neuroscience, 2018, 21, 207-217.	7.1	30
54	PO-381 Response project: chromatin regulators as biomarkers and drug targets in colorectal cancer. ESMO Open, 2018, 3, A171.	2.0	0

#	Article	IF	CITATIONS
55	ldentification of Novel Therapeutic Targets in Acute Megakaryoblastic Leukemia. Experimental Hematology, 2018, 64, S89-S90.	0.2	1
56	Necroptosis microenvironment directs lineage commitment in liver cancer. Nature, 2018, 562, 69-75.	13.7	283
57	MLL-fusion-driven leukemia requires SETD2 to safeguard genomic integrity. Nature Communications, 2018, 9, 1983.	5.8	43
58	SLAM-ITseq: Sequencing cell type-specific transcriptomes without cell sorting. Development (Cambridge), 2018, 145, .	1.2	29
59	Dorsal tegmental dopamine neurons gate associative learning of fear. Nature Neuroscience, 2018, 21, 952-962.	7.1	96
60	TCEA1 regulates the proliferative potential of mouse myeloid cells. Experimental Cell Research, 2018, 370, 551-560.	1.2	10
61	CD44 is a RAS/STAT5-regulated invasion receptor that triggers disease expansion in advanced mastocytosis. Blood, 2018, 132, 1936-1950.	0.6	18
62	CDK6 Antagonizes p53-Induced Responses during Tumorigenesis. Cancer Discovery, 2018, 8, 884-897.	7.7	53
63	BRD4 Degradation Is a Potent Approach to Block MYC Expression and to Overcome Multiple Forms of Stem Cell Resistance in Ph+ CML. Blood, 2018, 132, 1722-1722.	0.6	5
64	Abstract B37: RNAi and CRISPR/Cas9-based in vivo models for drug discovery. , 2018, , .		0
65	Abstract 5106: CRISPR/Cas9-based development of RNAi rat models for drug discovery. , 2018, , .		Ο
66	Abstract 1459: A mechanism counteracting micronucleation for maintenance of genomic integrity. , 2018, , .		0
67	Molecular role of the <scp>PAX</scp> 5― <scp>ETV</scp> 6 oncoprotein in promoting Bâ€cell acute lymphoblastic leukemia. EMBO Journal, 2017, 36, 718-735.	3.5	34
68	Histone Acetyltransferase Activity of MOF Is Required for <i>MLL-AF9</i> Leukemogenesis. Cancer Research, 2017, 77, 1753-1762.	0.4	38
69	BET-Bromodomain Inhibitors Engage the Host Immune System and Regulate Expression of the Immune Checkpoint Ligand PD-L1. Cell Reports, 2017, 18, 2162-2174.	2.9	244
70	Prediction of potent shRNAs with a sequential classification algorithm. Nature Biotechnology, 2017, 35, 350-353.	9.4	129
71	Impact of sample preparation on physical quantification of filling fats and oils in fresh and stored chocolate. European Journal of Lipid Science and Technology, 2017, 119, 1600359.	1.0	2
72	STAT3 Regulation of Citrate Synthase Is Essential during the Initiation of Lymphocyte Cell Growth. Cell Reports, 2017, 19, 910-918.	2.9	30

#	Article	IF	CITATIONS
73	An optimized lentiviral vector system for conditional RNAi and efficient cloning of microRNA embedded short hairpin RNA libraries. Biomaterials, 2017, 139, 102-115.	5.7	24
74	Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population. Blood, 2017, 129, 2882-2895.	0.6	74
75	CCL2 is a KIT D816V–dependent modulator of the bone marrow microenvironment in systemic mastocytosis. Blood, 2017, 129, 371-382.	0.6	24
76	Thiol-linked alkylation of RNA to assess expression dynamics. Nature Methods, 2017, 14, 1198-1204.	9.0	411
77	DNA Cross-Bridging Shapes a Single Nucleus from a Set of Mitotic Chromosomes. Cell, 2017, 170, 956-972.e23.	13.5	184
78	Topologically associating domains and chromatin loops depend on cohesin and are regulated by CTCF, WAPL, and PDS5 proteins. EMBO Journal, 2017, 36, 3573-3599.	3.5	620
79	Coupling shRNA screens with single-cell RNA-seq identifies a dual role for mTOR in reprogramming-induced senescence. Genes and Development, 2017, 31, 2085-2098.	2.7	53
80	Transcription elongation factors represent in vivo cancer dependencies in glioblastoma. Nature, 2017, 547, 355-359.	13.7	156
81	Loss-of-function genetic tools for animal models: cross-species and cross-platform differences. Nature Reviews Genetics, 2017, 18, 24-40.	7.7	159
82	A vital sugar code for ricin toxicity. Cell Research, 2017, 27, 1351-1364.	5.7	20
83	Synthetic lethality between the cohesin subunits STAG1 and STAG2 in diverse cancer contexts. ELife, 2017, 6, .	2.8	94
84	Tumor <i>Trp53</i> status and genotype affect the bone marrow microenvironment in acute myeloid leukemia. Oncotarget, 2017, 8, 83354-83369.	0.8	7
85	Polycomb protein RING1A limits hematopoietic differentiation in myelodysplastic syndromes. Oncotarget, 2017, 8, 115002-115017.	0.8	6
86	IncRNA requirements for mouse acute myeloid leukemia and normal differentiation. ELife, 2017, 6, .	2.8	54
87	Abstract 3452: The cohesin subunitSTAG1is a hardwired genetic dependency ofSTAG2mutant cancer cells. , 2017, , .		0
88	Abstract A20: Depletion of replication factor MCM7 is synthetically lethal to oncogenic KRAS expression. , 2017, , .		0
89	Id2 and E Proteins Orchestrate the Initiation and Maintenance of MLL-Rearranged Acute Myeloid Leukemia. Cancer Cell, 2016, 30, 59-74.	7.7	29
90	X-Linked inhibitor of apoptosis protein (XIAP) exhibits an essential role of patients' acute lymphoblastic leukemia cells growing in vivo. European Journal of Cancer, 2016, 69, S58-S59.	1.3	1

#	Article	IF	CITATIONS
91	Mapping the chemical chromatin reactivation landscape identifies BRD4-TAF1 cross-talk. Nature Chemical Biology, 2016, 12, 504-510.	3.9	43
92	Novel genetically engineered patient-derived xenograft (GEPDX) models reveal that XIAP plays an essential role for patients' all growing in mice. Experimental Hematology, 2016, 44, S105.	0.2	0
93	RNAi and CRISPR/Cas9 based in vivo models for drug discovery. European Journal of Cancer, 2016, 61, S208.	1.3	0
94	SWI/SNF regulates a transcriptional program that induces senescence to prevent liver cancer. Genes and Development, 2016, 30, 2187-2198.	2.7	48
95	An Inducible Retroviral Expression System for Tandem Affinity Purification Mass-Spectrometry-Based Proteomics Identifies Mixed Lineage Kinase Domain-like Protein (MLKL) as an Heat Shock Protein 90 (HSP90) Client. Molecular and Cellular Proteomics, 2016, 15, 1139-1150.	2.5	23
96	The CDK9 Inhibitor Dinaciclib Exerts Potent Apoptotic and Antitumor Effects in Preclinical Models of MLL-Rearranged Acute Myeloid Leukemia. Cancer Research, 2016, 76, 1158-1169.	0.4	100
97	An Inducible Retroviral Expression System for Tandem Affinity Purification Mass-Spectrometry-Based Proteomics Identifies Mixed Lineage Kinase Domain-like Protein (MLKL) as an Heat Shock Protein 90 (HSP90) Client. Molecular and Cellular Proteomics, 2016, 15, 1139-1150.	2.5	9
98	Abstract 4188: RNAi and CRISPR/Cas9 basedin vivomodels for drug discovery. , 2016, , .		1
99	MEK1 is required for the development of NRAS-driven leukemia. Oncotarget, 2016, 7, 80113-80130.	0.8	5
100	The Transcription Factor PU.1 Controls a Reversible Differentiation Program in Acute Myeloid Leukemia. Blood, 2016, 128, 3930-3930.	0.6	0
101	Uncovering Key Downstream Effectors of PU.1 Tumor Suppression in Acute Myeloid Leukemia. Blood, 2016, 128, 2698-2698.	0.6	Ο
102	Comparative functional analysis of the molecular network of 7 selected MLL fusion proteins. Experimental Hematology, 2015, 43, S95.	0.2	0
103	Functional-genetic dissection of HDAC dependencies in mouse lymphoid and myeloid malignancies. Blood, 2015, 126, 2392-2403.	0.6	48
104	CDK6 as a key regulator of hematopoietic and leukemic stem cell activation. Blood, 2015, 125, 90-101.	0.6	179
105	Disruption of STAT3 signalling promotes KRAS-induced lung tumorigenesis. Nature Communications, 2015, 6, 6285.	5.8	124
106	Identification of bromodomain-containing protein-4 as a novel marker and epigenetic target in mast cell leukemia. Leukemia, 2015, 29, 2230-2237.	3.3	21
107	The histone chaperone CAF-1 safeguards somatic cell identity. Nature, 2015, 528, 218-224.	13.7	244
108	Efficacy and Mechanism of Action of Volasertib, a Potent and Selective Inhibitor of Polo-Like Kinases, in Preclinical Models of Acute Myeloid Leukemia. Journal of Pharmacology and Experimental Therapeutics, 2015, 352, 579-589.	1.3	57

#	Article	IF	CITATIONS
109	Combining the differentiating effect of panobinostat with the apoptotic effect of arsenic trioxide leads to significant survival benefit in a model of t(8;21) acute myeloid leukemia. Clinical Epigenetics, 2015, 7, 2.	1.8	13
110	Control of a neuronal morphology program by an RNA-binding zinc finger protein, Unkempt. Genes and Development, 2015, 29, 501-512.	2.7	35
111	Toward understanding and exploiting tumor heterogeneity. Nature Medicine, 2015, 21, 846-853.	15.2	604
112	Pharmacological targeting of the Wdr5-MLL interaction in C/EBPα N-terminal leukemia. Nature Chemical Biology, 2015, 11, 571-578.	3.9	227
113	Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemotherapy and Pharmacology, 2015, 76, 35-46.	1.1	31
114	A genome-scale in vivo loss-of-function screen identifies <i>Phf6</i> as a lineage-specific regulator of leukemia cell growth. Genes and Development, 2015, 29, 483-488.	2.7	65
115	Cooperative loss of RAS feedback regulation drives myeloid leukemogenesis. Nature Genetics, 2015, 47, 539-543.	9.4	39
116	Transcriptional plasticity promotes primary and acquired resistance to BET inhibition. Nature, 2015, 525, 543-547.	13.7	414
117	Hyperactivation of mTORC1 and mTORC2 by multiple oncogenic events causes addiction to eIF4E-dependent mRNA translation in T-cell leukemia. Oncogene, 2015, 34, 3593-3604.	2.6	22
118	Effects of CCL2/CCR2 Blockade in Acute Myeloid Leukemia. Blood, 2015, 126, 1348-1348.	0.6	9
119	Identification of the Epigenetic Reader BRD4 As a Novel Potential Target in Ph+ CML. Blood, 2015, 126, 1571-1571.	0.6	0
120	Identification of the Epigenetic Reader BRD4 As a Novel Therapeutic Target in JAK2 V617F+ MPN Cells. Blood, 2015, 126, 2829-2829.	0.6	0
121	Reversible Suppression of Cyclooxygenase 2 (COX-2) Expression In Vivo by Inducible RNA Interference. PLoS ONE, 2014, 9, e101263.	1.1	11
122	BRD4: A BET(ter) target for the treatment of AML?. Cell Cycle, 2014, 13, 689-690.	1.3	25
123	Regulation of NO Synthesis, Local Inflammation, and Innate Immunity to Pathogens by BET Family Proteins. Molecular and Cellular Biology, 2014, 34, 415-427.	1.1	61
124	Stage-specific control of early B cell development by the transcription factor Ikaros. Nature Immunology, 2014, 15, 283-293.	7.0	194
125	MLL3 Is a Haploinsufficient 7q Tumor Suppressor in Acute Myeloid Leukemia. Cancer Cell, 2014, 25, 652-665.	7.7	274
126	Differentiation therapy for the treatment of t(8;21) acute myeloid leukemia using histone deacetylase inhibitors. Blood, 2014, 123, 1341-1352.	0.6	107

#	Article	IF	CITATIONS
127	Development of siRNA Payloads to Target <i>KRAS</i> -Mutant Cancer. Cancer Discovery, 2014, 4, 1182-1197.	7.7	93
128	ZRF1 controls the retinoic acid pathway and regulates leukemogenic potential in acute myeloid leukemia. Oncogene, 2014, 33, 5501-5510.	2.6	22
129	PAX5 loss imposes a reversible differentiation block in b-progenitor acute lymphoblastic leukemia. Experimental Hematology, 2014, 42, S46.	0.2	0
130	Comparative functional analysis of the molecular network of 7 selected MLL fusion proteins. Experimental Hematology, 2014, 42, S60.	0.2	0
131	In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nature Medicine, 2014, 20, 1138-1146.	15.2	242
132	Pax5 loss imposes a reversible differentiation block in B-progenitor acute lymphoblastic leukemia. Genes and Development, 2014, 28, 1337-1350.	2.7	73
133	CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma. Genes and Development, 2014, 28, 1800-1814.	2.7	167
134	Preclinical efficacy of MEK inhibition in Nras-mutant AML. Blood, 2014, 124, 3947-3955.	0.6	79
135	Downregulation of RUNX1/CBFβ by MLL fusion proteins enhances hematopoietic stem cell self-renewal. Blood, 2014, 123, 1729-1738.	0.6	29
136	Abstract 2974: RNAi mouse models: Revolutionizing drug discovery in vivo. , 2014, , .		0
137	Abstract 2935: RNAi screen identifies therapeutic targets in hepatocellular carcinoma. , 2014, , .		0
138	Abstract 5533: RNAi-mediated depletion of histone deacetylases highlights the potential for isoform-specific inhibitors in B-cell lymphoma and acute myeloid leukemia. , 2014, , .		1
139	Abstract 4273: An enhanced microRNA backbone for potent single-copy RNAi. , 2014, , .		1
140	Abstract PR07: RNAi mouse models: Revolutionizing drug discovery in vivo. , 2014, , .		0
141	AML Genotype-Specific and Non-Specific Regulation of Mesenchymal Stromal Cell Transcriptome in the Bone Marrow Microenvironment. Blood, 2014, 124, 1586-1586.	0.6	5
142	Preclinical Efficacy of MEK Inhibition in Nras Mutant Acute Myeloid Leukemia. Blood, 2014, 124, 3753-3753.	0.6	0
143	RUNX1/CBFÎ ² Dosage Is Critical for MLL Leukemias Development. Blood, 2014, 124, 2187-2187.	0.6	0
144	The Polycomb complex PRC2 supports aberrant self-renewal in a mouse model of MLL-AF9;NrasG12D acute myeloid leukemia. Oncogene, 2013, 32, 930-938.	2.6	102

#	Article	IF	CITATIONS
145	An Optimized microRNA Backbone for Effective Single-Copy RNAi. Cell Reports, 2013, 5, 1704-1713.	2.9	563
146	Recruitment of the MLL complex via specific interaction of the p30 variant of C/EBPα with Wdr5 is essential for development of acute myeloid leukemia. Experimental Hematology, 2013, 41, S20.	0.2	0
147	Elucidating the molecular mechanism of action of cancer drugs in the second decade of the new millennium. Experimental Hematology, 2013, 41, S9.	0.2	0
148	Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated <i>Myc</i> regulation. Genes and Development, 2013, 27, 2648-2662.	2.7	394
149	Abstract B16: Inhibition of RNA Polymerase I transcription by CX-5461 as a therapeutic strategy for the cancer-specific activation of p53 in highly refractory haematological malignancies. , 2013, , .		1
150	Bromodomain-Containing Protein 4 (BRD4): A Novel Marker and Drug Target Expressed In Neoplastic Cells In Advanced Mast Cell Neoplasms. Blood, 2013, 122, 3747-3747.	0.6	1
151	Inhibition Of RNA Polymerase I Transcription By CX-5461 As a Therapeutic Strategy For The Cancer-Specific Activation Of p53 In Highly Refractory Haematological Malignancies. Blood, 2013, 122, 3941-3941.	0.6	4
152	Proteomic, Gene Expression, and Micro-RNA Analysis Of Bone Marrow Mesenchymal Stromal Cells In Acute Myeloid Leukemia Identifies Pro-Inflammatory, Pro-Survival Signatures In Vitro and In Vivo. Blood, 2013, 122, 3685-3685.	0.6	2
153	Investigating Synthetic Lethality Between mTOR Hyperactivation and Cap-Dependent mRNA Translation In a Receptor Tyrosine Kinase Driven Model Of Acute T-Cell Leukemia. Blood, 2013, 122, 3913-3913.	0.6	0
154	Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. Genes and Development, 2012, 26, 120-125.	2.7	344
155	A cluster of cooperating tumor-suppressor gene candidates in chromosomal deletions. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 8212-8217.	3.3	138
156	NKT cell adjuvant-based tumor vaccine for treatment of myc oncogene-driven mouse B-cell lymphoma. Blood, 2012, 120, 3019-3029.	0.6	67
157	58 Proffered Paper: Next Generation RNAi Mouse Models for Drug Discovery and Toxicology Assessment. European Journal of Cancer, 2012, 48, S14.	1.3	0
158	45 Next Generation RNAi Mouse Models for Drug Discovery and Toxicology Assessment. European Journal of Cancer, 2012, 48, 16.	1.3	0
159	An insertional mutagenesis screen identifies genes that cooperate with Mll-AF9 in a murine leukemogenesis model. Blood, 2012, 119, 4512-4523.	0.6	22
160	A pipeline for the generation of shRNA transgenic mice. Nature Protocols, 2012, 7, 374-393.	5.5	146
161	Cancer stem cell definitions and terminology: the devil is in the details. Nature Reviews Cancer, 2012, 12, 767-775.	12.8	599
162	Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia (AML). Oncotarget, 2012, 3, 1588-1599.	0.8	144

#	Article	IF	CITATIONS
163	RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature, 2011, 478, 524-528.	13.7	1,656
164	A Rapid and Scalable System for Studying Gene Function in Mice Using Conditional RNA Interference. Cell, 2011, 145, 145-158.	13.5	278
165	Functional Identification of Optimized RNAi Triggers Using a Massively Parallel Sensor Assay. Molecular Cell, 2011, 41, 733-746.	4.5	193
166	Forward and Reverse Genetics through Derivation of Haploid Mouse Embryonic Stem Cells. Cell Stem Cell, 2011, 9, 563-574.	5.2	208
167	Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nature Biotechnology, 2011, 29, 79-83.	9.4	235
168	Flt3-ITD alters chemotherapy response in vitro and in vivo in a p53-dependent manner. Experimental Hematology, 2011, 39, 473-485.e4.	0.2	27
169	Reversible suppression of an essential gene in adult mice using transgenic RNA interference. Proceedings of the National Academy of Sciences of the United States of America, 2011, 108, 7113-7118.	3.3	49
170	An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes and Development, 2011, 25, 1628-1640.	2.7	242
171	Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia. Nature Cell Biology, 2010, 12, 372-379.	4.6	316
172	p53 loss promotes acute myeloid leukemia by enabling aberrant self-renewal. Genes and Development, 2010, 24, 1389-1402.	2.7	148
173	An RNAi Screen Reveals a Pattern of Addiction to Epigenetic Pathways That Distinguishes MLL-AF9 Leukemia From Normal Hematopoietic Cells. Blood, 2010, 116, 65-65.	0.6	0
174	Mouse models of human AML accurately predict chemotherapy response. Genes and Development, 2009, 23, 877-889.	2.7	235
175	Functional Identification of Tumor-Suppressor Genes through an In Vivo RNA Interference Screen in a Mouse Lymphoma Model. Cancer Cell, 2009, 16, 324-335.	7.7	155
176	TAp63 induces senescence and suppresses tumorigenesis in vivo. Nature Cell Biology, 2009, 11, 1451-1457.	4.6	221
177	A Reconfigured Pattern of MLL Occupancy within Mitotic Chromatin Promotes Rapid Transcriptional Reactivation Following Mitotic Exit. Molecular Cell, 2009, 36, 970-983.	4.5	173
178	Effects of the Flt3 ITD on response to chemotherapy in a murine model of acute myeloid leukemia. Journal of Clinical Oncology, 2009, 27, 7060-7060.	0.8	0
179	An Oncogenomics-Based In Vivo RNAi Screen Identifies Tumor Suppressors in Liver Cancer. Cell, 2008, 135, 852-864.	13.5	404
180	SnapShot: Genetic Mouse Models of Cancer. Cell, 2007, 129, 838.e1-838.e2.	13.5	9

#	Article	IF	CITATIONS
181	Transcriptional basis of KRAS oncogene-mediated cellular transformation in ovarian epithelial cells. Oncogene, 2004, 23, 4536-4555.	2.6	76
182	Effective use of high-dose chemotherapy and autologous stem cell rescue for relapsed adult Wilms' tumor and a novel alteration in intron 1 of the WT1 gene. Journal of Pediatric Hematology/Oncology, 2004, 26, 820-3.	0.3	2
183	Squamous cutaneous epithelial cell carcinoma in two CML patients with progressive disease under imatinib treatment. European Journal of Haematology, 2003, 70, 231-234.	1.1	35
184	Dissection of signal-regulated transcriptional modules by signaling pathway interference in oncogene-transformed cells. Advances in Enzyme Regulation, 2003, 43, 379-391.	2.9	8
185	Gene expression profiling in RAS oncogene-transformed cell lines and in solid tumors using subtractive suppression hybridization and cDNA arrays. Advances in Enzyme Regulation, 2002, 42, 63-82.	2.9	19
186	A genome-wide survey of RAS transformation targets. Nature Genetics, 2000, 24, 144-152.	9.4	265
187	Gene expression profiling of fibroblasts resistant toward oncogene-mediated transformation reveals preferential transcription of negative growth regulators, Oncogene, 1999, 18, 5448-5454.	2.6	25